



# การประชุมวิชาการประจำปี

คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น  
ครั้งที่ 26 ประจำปี 2553

Faculty of Medicine KhonKaen University



## *Patient Safety Care*

ระหว่างวันที่ 12 - 15 ตุลาคม 2553

ณ ห้องบรรยาย 1 - 4

อาคารเตรียมวิทยาศาสตร์คลินิก

คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น



36. การประเมินคุณภาพของอุปกรณ์กำบังรังสี อมรรัตน์ มั่งงา, ปรีศนา ตราชู, อุทัย ขาลืออ่อน, สายพิน โคตรตาแสง, ศิรินารถ ปรีชาตเกษตร, วราภรณ์ ศิลาวิเศษ, อรปภา ผิวเหลือง, บรรจง เชื้อนแก้ว, เพชรกร หาญพานิชย์, จิตเจริญ ไชยาคำ.....	211
37. ระดับ Cystatin C ในผู้ป่วยเบาหวาน ศิริพร ภัทริกัจจาจร, ดวงเดือน ธรรมนารถสกุล, ลี้มทอง พรหมดี, ยาวลักษณ์ วีระเจตกุล, มานะ จันทร์ชาติ.....	212
38. การศึกษาเปรียบเทียบการประเมินกระบวนการจัดการเรียนการสอน วิชา การออกแบบกราฟิก ทางการแพทย์ ของนักศึกษาเวชนิทัศน์ ปี 1/ 2551 และ 1/2552 จงเจริญ เมตตา, ทรงพล อุบัติกุล, ดุษฎี มุสิกโปดก, สันติพงษ์ แสนรักษ์.....	213
39. การศึกษาเปรียบเทียบการประเมินกระบวนการจัดการเรียนการสอน วิชามหกายวิภาคศาสตร์ ของมนุษย์โดยนักศึกษาเวชนิทัศน์ ปี 1/ 2551 และ 1/2552 จงเจริญ เมตตา, โกวิท ไชยวิมางค, พรทิพย์ บุญเรืองศรี, ยรรยง ทุมแสน, พิพัฒน์พงษ์ แคนลา.....	214
40. การศึกษาเปรียบเทียบปัญหาการใช้โปรแกรม Adobe Audition ของนักศึกษาเวชนิทัศน์ ปีการศึกษา 1/ 2551 และ 1/2552 จงเจริญ เมตตา, ทรงพล อุบัติกุล, ดุษฎี มุสิกโปดก, สันติพงษ์ แสนรักษ์.....	215
41. การศึกษาเปรียบเทียบปัญหาการใช้โปรแกรม Adobe Photoshop ในการออกแบบกราฟิกคอมพิวเตอร์ ทางการแพทย์ ของนักศึกษาเวชนิทัศน์ ปี 1/2551 และ 1/ 2552 จงเจริญ เมตตา, ทรงพล อุบัติกุล, ดุษฎี มุสิกโปดก, สันติพงษ์ แสนรักษ์.....	216
42. ผลการสำรวจความคิดเห็นที่มีต่อครีนิครินทร์เวชสาร สมปอง จันทะคราม .....	217

## PROCEEDING

43. Severe Adverse Reactions to Antiepileptic Drugs in Children Kanokwan Choosakul Kaewkhew, Narong Auvichayapat.....	221
44. Intelligent Quotient In Childhood Acute Lymphoblastic Leukemia Received CNS Prophylaxis: With Or Without Cranial Irradiation Dara Mairiang, Chanyut Suphakunpinyo, Patcharee Komwilaisak .....	224
45. Monosodium Glutamate Consumption is Related to Obesity in Humans Tonkla Insawang, Supattra Pethlert, Tueanjit Khampitak, Patcharee Boonsiri, Roongpet Tungrassameeprasert, Chadamas Pinitsoontorn, Vitoon Prasongwattana, Puangrat Yongvanit, Premjai Areejitranusorn, Ubon Cha'on.....	226
46. การจัดการตนเองในผู้ป่วยโรคลิ้นหัวใจที่ได้รับยาต้านการแข็งตัวของเลือดชนิดรับประทาน นลัทพร สืบเสาะ, ขวณพิศ ทำนอง.....	229
47. Protective Effect of Tetrahydrocurcumin Against Oxidative Stress in Mice Exposed to Cadmium Wanida Donpunha, Upa Kukongviriyapan, Veerapol Kukongviriyapan, Patchareewan Pannangpetch, Poungnat Pakdeechote, Kwanjit Sompamit.....	231
48. Oxidative Stress and HDL Cholesterol Levels are Independent Predictors of the Severity of Coronary Artery Stenosis in Thai patients with Coronary Heart Disease Suphawadee Phababpha, Upa Kukongviriyapan, Pyatat Tatsanavivat, Veerapol Kukongviriyapan, Poungnat Pakdeechote, Laddawan Senggunprai, Phongsak Intharaphet, Sudhithep Duangsorn, Kasem Tantipanichteerakul, Vichai Senthong, Nantarat Komanasin, Nongnuch Settasatian, Chatri Settasatian .....	235
49. Effect of Curcumin on Hemodynamic Status and Aortic Elasticity in L-NAME Hypertensive Rat Saowanee Nakmareong, Upa Kukongviriyapan, Poungnat Pakdeechote, Veerapol Kukongviriyapan, Bunkerd Kongyingyoes, Parichat Pracheney, Kwanjit Sompamit .....	240



50.	Mean Length of Utterances of Thai Children Aged 2-4 Years Old in Khon Kaen Municipality, Thailand. Amornrat Pongjanyakul, Sumalee Dechongkit, Kanjalak Khantapasuntara, Monnipa Chutiboot .....	243
51.	Effects of Streblus Asper Leaves Extract on Scopolamine-induced Learning Deficits in Male Rats. Rakwarinn Wannasin, Jintana Sattayasai, Prapawadee puapairoj, Tarinee Arkaravichien .....	246
52.	Cloning of Specific T Cell Opisthorchis Viverrini in Balb/c Mice Chamraj Kaewraemruaen, Rasana W. Sermswan, Jaruek Charoensup, Surasakdi Wongratanacheewin .....	250
53.	Glibenclamide Increase Risk of Hospitalized Hypoglycemia in Srinagarind Hospital Kasemsap N, Yaowapruet W, Chotimongkol R, Pratipanawatr T .....	254
54.	Roselle Extract and Gallic Acid Improve Vascular Reactivity of Diabetic Rats Anunkaorn Mantrud, Patchareewan Pannangpetch, Bunkerd Kongyingyoes, Upa Kukongviriyapan, Sirinapha chuant, Saowanee Nakmareong, Arunporn Itharat .....	257
55.	The Cytokine Level in Cervicovaginal Lavages (CVLs) from Women with Grade 1 Cervical Intraepithelial Neoplasia (CIN I) is Associated with HPV Clearance Praphatson Malat, Chamsai Pientong, Tipaya Ekalaksananan, Nicha Charoensri, Bunkerd Kongyingyoes, Bandit Chumworathayi .....	262
56.	Antagonistic Growth Inhibitory Effect of Isomorellinol with Chemotherapeutic Agents Against Human Cholangiocarcinoma KKU-M156 Cell Line Wareeporn Wattanawongdon, Chariya Hahnvanawong, Natthinee Anantachoke, Thidarut Bunmars, Wichitra Tassaneeyakul, Banjob Sripa, Vichai Reutrakul .....	265
57.	Fluconazole Susceptibility in Candida dubliniensis Suphachira Srichangwang, Kunyaluk Chaicumpar .....	269
58.	Effects of Compounds from Clinacanthus Nutans on Dengue Virus Type 2 Infection Sujittaporn Sittiso, Tipaya Ekalaksananan, Chamsai Pientong, Santi Sakdarat, Nicha Charoensri, Bunkerd Kongyingyoes .....	272
59.	Constructed Antisense mRNA-Producing Recombinant Plasmid to Study Gene Function in Mycobacterium Tuberculosis Akkpon Hanrin, Kunyaluk Chaicumpa, Wiset Namwat .....	276
<b>INDEX OF AUTHORS .....</b>		<b>277</b>



# Antagonistic Growth Inhibitory Effect of Isomorellinol with Chemotherapeutic Agents Against Human Cholangiocarcinoma KKU-M156 Cell Line

Wareeporn Wattanawongdon<sup>1,7,8</sup>, Chariya Hahnvajjanawong<sup>1,7,8</sup>, Natthinee Anantachoke<sup>2,8</sup>, Thidarut Bunmars<sup>3,7</sup>, Wichitra Tassaneeyakul<sup>4,7</sup>, Banjob Sripa<sup>5,7</sup>, Vichai Reutrakul<sup>6,8</sup>

<sup>1</sup>Department of Microbiology, <sup>3</sup>Parasitology, <sup>4</sup>Pharmacology, <sup>5</sup>Pathology, <sup>7</sup>Liver Fluke and Cholangiocarcinoma Research Center (LFCRC) and <sup>8</sup>Center of Excellence for Innovation in chemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. <sup>2</sup>Department of Pharmacognosy, Faculty of Pharmacy and <sup>6</sup>Department of Chemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.

E-mail: kikanooky@hotmail.com

**Key words:** cholangiocarcinoma KKU-M156 cells, isomorellinol, 5-Fluorouracil, paclitaxel, antagonistic effect

## Introduction

Cholangiocarcinoma (CCA) is a malignant tumor arising from bile duct epithelial cells, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents<sup>1</sup>. Our previous studies demonstrated that isomorellinol (Figure 1) inhibited growth, induced cell cycle arrest and apoptosis in CCA cell lines<sup>2</sup>. This study aims to examine the growth inhibitory effects of isomorellinol, 5-Fluorouracil (5-FU) and paclitaxel and their combination effects on human CCA KKU-M156 cell line.




Figure 1 Chemical structure of isomorellinol.

## Materials and Methods

### Chemicals

RPMI 1640 medium, fetal bovine serum (FBS), Fungizone, Penicillin-Streptomycin were purchased from Gibco (Rockville, MD, USA). 5-FU and paclitaxel were obtained from Boryung Pharmaceutical Co. LTD

(Korea). Isomorellinol was isolated from *Garcinia hanburyi* Hook.f. (family Guttiferae) using bioassay-directed fractionation. All other chemicals were analytical grade.

### Human CCA cell line

The human CCA cell line, KKU-M156 was established from CCA patients in the Faculty of Medicine, Khon Kaen University, Thailand. Cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C in a 5% CO<sub>2</sub> incubator.

### Cell growth inhibition assay

The sulforhodamine B (SRB) assay was performed to assess growth inhibition using a colorimetric assay, which estimates cell number indirectly by staining total cellular protein with the dye SRB<sup>3</sup>. Briefly, human CCA KKU-M156 cell (1x10<sup>4</sup> cells/well) was seeded in 96-well microtiter plates and incubated at 37°C for 24 h to allow for cell attachment. Cells were treated with 0, 0.5, 1, 2, 4 and 8 µM/well for isomorellinol; 0, 4, 8, 16, 32 and 64 µM/well for 5-FU; and 0, 0.01, 0.02, 0.04 and 0.08 µM/well for paclitaxel. The plates were incubated for 1 h (d0) and 72 h (d3) at 37 °C. At the end of each exposure time, the medium was removed and the cells were fixed with 20% (w/v) trichloroacetic acid

at 4°C for 1 h, stained for 30 min with 0.4% (w/v) SRB dissolved in 1% acetic acid for 30 min, and washed four times with 1% acetic acid. The protein-bound dye was solubilized with 10 mM Tris base (pH 10). The absorbance (OD) was measured using a microplate reader (Sunrise-TECAN, USA) at 510 nm. Percentage of cell survival was calculated using the formula: Percentage of cell survival = [(OD test sample at d 3 - OD d 0)/(OD control at d 3 - OD d 0)] x 100. Dose-response curves were plotted, and 50% growth inhibitory concentrations of isomorellinol or drugs ( $IC_{50}$ ) were calculated through computation with the CalcuSyn software program (Biosoft, Cambridge, UK).

#### Evaluation of drug interaction

Combination assays were performed using appropriate concentrations of isomorellinol with appropriate concentrations of 5-FU or paclitaxel. Cells treated with the same final concentrations of the isomorellinol or chemotherapeutic drugs alone were also examined. Cell growth inhibition was determined using the SRB assay, as previously described. In the assessment of the combination effects (i.e., synergism,

additivity or antagonism), the combination index (CI) method according to Chou and Talalay was used<sup>4</sup>.

#### Statistical analysis

Data were expressed as mean  $\pm$  standard errors. Comparisons between untreated control cells and the treated cells were made using pair *t*-test. Differences were considered significant at <sup>a</sup>*p*<0.05, <sup>b</sup>*p*<0.01 and <sup>c</sup>*p*<0.001. All analyses were performed using SPSS version 10.0 (spss Inc, USA).

### Results

#### Effect of isomorellinol, 5-FU and paclitaxel alone on KKU-M156 cell growth

The treatment of KKU-M156 cell with isomorellinol, 5-FU and paclitaxel markedly inhibited cell growth in a dose-dependent manner (Figure 2). The  $IC_{50}$  values of isomorellinol and these chemotherapeutic drugs are shown in Table 1. The anticancer potency of isomorellinol is comparable to these two drugs. These results demonstrated the efficacy of isomorellinol and these drugs in KKU-M156 cell growth inhibition.




Figure 2 Growth inhibitory effects of isomorellinol (2A), 5-FU (2B) and paclitaxel (2C) on KKU-M156 cell. Cells were treated with DMSO or indicated amount of isomorellinol and these chemotherapeutic drugs for 72 h. Cell viability was determined by SRB assay. Each value represents the mean  $\pm$  S.E. of three independent experiments.



**Table 1** The  $IC_{50}$  values of the Isomorellinol and chemotherapeutic drugs on CCA cell lines.

Drug	$IC_{50}$ value ( $\mu$ M)
Isomorellinol	$2.4 \pm 0.05$
5-FU	$10.03 \pm 0.16$
Paclitaxel	$0.045 \pm 0.40$

#### Combination effects of isomorellinol with chemotherapeutic drugs on cell growth


Based on the data showing efficacy of isomorellinol, 5-FU and paclitaxel in KKU-M156 cell, next we assessed their effects in combinations on KKU-M156 cell growth and analyzed the data for a possible synergism ( $CI < 1$ ), additivity ( $CI = 1$ ) or antagonism ( $CI > 1$ ) by using median effect analysis. As shown in Figure 3, the combinations of isomorellinol with both drugs resulted in antagonistic effects in all combinations tested.

#### Discussion

Because of the simple, flexible, rapid and economic features, investigations of drug combinations *in vitro* can frequently be used for prospective or retrospective studies in animal systems or in clinical settings. *In vitro* studies may also provide the rationale for drug combina-

tions based on quantitation of synergism or antagonism. In this study, by using the median-effect principle and the combination index-isobologram technique, we were capable of analyzing the growth inhibitory effects of isomorellinol, 5-FU or paclitaxel used alone or in combinations. Our results demonstrated that isomorellinol and both chemotherapeutic drugs mediated significant growth inhibitory effects on KKU-M156 cell in a dose-dependent manner. Isomorellinol combined with 5-FU or paclitaxel resulted in antagonistically growth inhibitory activity at all concentrations tested in KKU-M156 cell.

In previous reports, 5-FU was found to inhibit DNA and RNA synthesis of cell which usually occur during S phase of cell cycle. Whereas, paclitaxel was found to interfere with normal function of microtubule break down leading to cell mitotic inhibition. Previously, we found that isomorellinol induced cell cycle arrest at G0/G1 phase in KKU-M156 cells (data not shown). Therefore, the antagonistic effects of the combinations may be due to the G0/G1 phase arrest of cell cycle caused by isomorellinol leading to decrease number of cell in S- and G2- phase which are target for 5-FU and paclitaxel, respectively.



**Figure 3** The combination effects of isomorellinol with 5-FU or paclitaxel on KKU-M156 (3A, 3B). Curve with solid lines are computer simulated fa-CI plots, base on the parameters ( $m$  and  $D_m$  values) for the combination of isomorellinol with 5-FU or paclitaxel.



### Conclusion

The growth inhibitory activity of 5-FU or paclitaxel, as a single agent, may be reduced by combination with isomorellinol.

### Acknowledgments

We wish acknowledge the Liver Fluke and Cholangiocarcinoma Research Center (LFCRC), Faculty of Medicine, Khon Kaen University for permission to use scientific instruments during this study. This work was funded by a research grant from the Center for Innovation in Chemistry: Post graduate Education and Research Program in Chemistry (PERC-CIC) (2005-2007).

### References

1. Lazaridis KN, Gores GJ. Cholangiocarcinoma. *Gastroenterology* 2005; 128:1655–67.
2. Hahnvajjanawong C, Boonyanugomol W, Nasomyon T, Loilome W, Namwat N, Anantachoke N, et al. Apoptotic activity of caged xanthenes from *Garcinia hanburyi* in cholangiocarcinoma cell lines. *World J Gastroenterology* 2010; 16:2235-43.
3. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* 1990; 82:1107–12.
4. Chou, T.C.; Talalay, P. *Trends Pharmacol. Sci.* 1983; 4,450-454.